CML is a malignant proliferative disease derived from BM hematopoietic stem cells, and TKIs function by inhibiting the tyrosine kinase activity of the pathogenic protein BCR::ABL1 in CML cells. Here, ABL1 is linked to glycogen storage disease VI.